| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
ACELYRIN, INC.$2.27
+0.03 (+1.34%)
D 28Pipeline Score Richly Valued Pharma · Clinical
Market Cap
229.16 M
EPS
-2.69
P/E Ratio
-
Value Trade
9.30 M
-9.92 %
Week
3.65 %
1 Month
7.08 %
3 Month
-46.71 %
6 Month
-90.13 %
5 Year
-90.13 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
4.08 M
52 Week Range
1.85 - 7.25
% held by Insiders
16.75 %
% held by Institutions
42.5 %
Enterprise Value
-175.46 M
Total Shares
100.95 M
Short %
4.25 %
Float Shares
77.87 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-01-06 | Lonigutamab (subcutaneous delivery) | Phase 2 data readout | Phase 2 | — | – | – | – |
2025-01-06 | Lonigutamab (subcutaneous delivery) | Phase 2 data readout | Phase 2 | — | – | – | – |
2025-01-06 | Lonigutamab (subcutaneous delivery) | Phase 2 data readout | Phase 2 | — | – | – | – |
Drug Pipeline Intelligence
D28
Pipeline Score $12M
Pipeline ValueRichly Valued
Valuation Signal3
Drugs Scored0.1x
rNPV / MCap Top 32%
Micro Cap (rank 629 of 923)
Percentile RankACELYRIN, INC. faces pipeline headwinds (28/100), with $547M risk-adjusted pipeline value, led by ABY-035 in Psoriatic Arthritis (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABY-035 Monoclonal antibody | Psoriatic Arthritis | Phase 2 | NCT04713072 | 26% | $455M | COMPLETED | 129 | - | - | Jan 27, 2022 | - | Feb 9, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
lonigutamab | Thyroid Eye Disease | Phase 2 | 2025-01-06 | robust efficacy in TED patients comparable to the IV administered standard of care; no reported cases of hearing impairment, hyperglycemia or menstrual disorders to date Read More | ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease Read More | |
lonigutamab | Thyroid Eye Disease | Phase 2 | 2025-01-06 | robust efficacy in TED patients comparable to the IV administered standard of care; no reported cases of hearing impairment, hyperglycemia or menstrual disorders to date Read More | ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease Read More | |
lonigutamab | Thyroid Eye Disease | Phase 2 | 2025-01-06 | robust efficacy in TED patients comparable to the IV administered standard of care; no reported cases of hearing impairment, hyperglycemia or menstrual disorders to date Read More | ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SLRN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SLRN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How SLRN ranks across every disease it competes inCompetitive Position is a premium feature
See how SLRN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial